ADAM CASEY: Open Payments
NPI 1548735673 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,904 in 90 payments from 18 companies in 2025. Trend: 2023 $1,086 · 2024 $1,262 · 2025 $1,904
Food & beverage: $1,820Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $500 |
| Madrigal Pharmaceuticals | 10 | $357 |
| Janssen Biotech, Inc. | 8 | $203 |
| QOL Medical, LLC | 8 | $170 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $153 |
| Aimmune Therapeutics, Inc. | 5 | $100 |
| GENZYME CORPORATION | 3 | $69 |
| Ardelyx, Inc. | 4 | $63 |
| Novo Nordisk Inc | 2 | $59 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $47 |
Products named: REZDIFFRA, RINVOQ, TREMFYA, Sucraid, EOHILIA, LINZESS, SKYRIZI, DUPIXENT.
Industry payments across NV — which companies pay providers there.
